GLP-1 and Pregnancy: Semaglutide, Tirzepatide and Planning
What current labels say about GLP-1 medicines before and during pregnancy, accidental exposure, contraception and why planning must be product-specific.
Pregnancy planning with a GLP-1 medicine needs a product-specific medical plan. Weight-loss treatment is not recommended during pregnancy. If you become pregnant while taking one of these medicines, contact the prescriber and pregnancy-care team promptly to review the medicine, its indication and the timing of exposure.
What the current labels say
| Medicine | Key US label information |
|---|---|
| Ozempic (semaglutide) | Stop at least two months before a planned pregnancy; pregnancy use requires a benefit-risk assessment |
| Wegovy (semaglutide) | Discontinue when pregnancy is recognized for weight reduction; the label treats advanced-fibrosis MASH as a separate benefit-risk decision |
| Mounjaro (tirzepatide) | Human pregnancy data are insufficient; use during pregnancy only if potential benefit justifies potential fetal risk |
Sources: Ozempic label, Wegovy label, Mounjaro label. These are label summaries, not instructions to continue treatment without assessment. Poorly controlled diabetes can also harm pregnancy, so medication review must include a plan for the underlying condition.
Do not calculate a washout from half-life alone
A drug's half-life is not a complete pregnancy-planning recommendation. Semaglutide labeling includes a two-month interval before planned pregnancy. Do not replace that with a shorter calculation of five half-lives, or apply the same interval automatically to every drug. The team should provide written timing for the exact product, indication and circumstances.
The current Wegovy label includes indication-specific pregnancy language for MASH; this is another reason a universal “every GLP-1 is formally contraindicated in every situation” statement is inaccurate. It is not evidence that treatment is safe in pregnancy.
What accidental-exposure studies can tell us
A 2024 prospective observational study included 168 pregnancies with first-trimester GLP-1 exposure, plus diabetes and overweight/obesity comparison groups. It did not find a statistically significant increase in major birth defects, but estimates were imprecise and the exposed group was small. Dao and colleagues, BMJ Open.
That finding can inform counseling after accidental exposure. It cannot prove safety for planned use throughout pregnancy, establish equivalence among individual drugs or rule out uncommon harms. Exposure alone is also not a diagnosis of fetal harm. A clinician can put the timing, other medicines and underlying health conditions into context.
Tirzepatide and oral contraception
Mounjaro labeling advises switching to non-oral contraception or adding a barrier method for four weeks after starting treatment and for four weeks after each dose escalation, because delayed gastric emptying may affect oral hormonal contraception. Mounjaro prescribing information.
Ask the prescriber or pharmacist how that applies to the contraceptive method you use. Our Mounjaro dose guide explains the distinction between a prescribed dose change and an automatic escalation chart.
Prepare for the clinical conversation
Have the following details ready:
- Exact medicine, formulation and prescribed strength.
- Date of the last dose and any recent dose changes.
- Why it was prescribed, including diabetes or another condition.
- Pregnancy timing, if known, and all other medicines.
- Current contraception or breastfeeding status, where relevant.
Ask who will coordinate changes, how the underlying condition will be managed and when follow-up is needed. Avoid starting a replacement diabetes medicine or a supplement on the basis of a general article.
Breastfeeding and treatment after delivery
Breastfeeding is a separate assessment from pregnancy. Labeling differs by medicine and formulation; for example, the Wegovy label specifically advises against breastfeeding during treatment with its tablets. A blanket restart date after delivery is inappropriate. Wegovy label, lactation section.
If treatment is interrupted, our weight-regain evidence review explains what withdrawal trials measured. Those studies do not establish a pregnancy or postpartum weight-loss plan.
Sources and revision
Labels and the primary exposure study were checked September 15, 2026. This update removes unsupported cohort numbers, unverified quotations, universal contraindication claims and half-life-derived stopping schedules. Editorial synthesis with AI assistance; no independent obstetric or physician review is claimed.
Tags
More in GLP-1 Medications
Written By
Metabolic Science Editorial
Research and editorial content
Metabolic Science publishes educational articles with AI assistance. Our articles link to their sources and explain research limitations. They are not a substitute for care from a qualified health professional. No independent medical review is claimed.
Editorial Standards
This article follows our strict editorial guidelines. Content is prepared with AI assistance and includes source links. No independent medical review is claimed. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.